US81578P1066 - Common Stock
NASDAQ:SEER (11/28/2022, 11:48:07 AM)-0.24 (-3.72%)
|GICS Sector||Health Care|
|GICS Industry||Life Sciences Tools & Services|
|Earnings (Last)||11-08 2022-11-08/amc||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||4.07%||Inst Owners||69.98%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm is engaged in developing transformative products. The Company’s initial product, the Proteograph product suite leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. The Proteograph product suite is an integrated solution that is comprised of consumables, an automation instrument, and software. Its approach is based on engineered NPs that enable unbiased sampling of intact proteins across the dynamic range of the proteome, capturing a myriad of molecular information at the level of protein variants as well as protein-protein interactions (PPIs). The company is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The firm is initially focused on research applications for the Proteograph product Suite and are selling and marketing the Proteograph for research use only (RUO) eliminates the need for complex workflows required by other unbiased approaches.
3800 Bridge Parkway, Suite 102
Redwood City CALIFORNIA
Proteograph utility is demonstrated as market interest continues to build with multiple studies underway
Proteograph utility is demonstrated as market interest continues to build with multiple studies underway...
REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for...
Here you can normally see the latest stock twits on SEER, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.